Unverified50% confidenceFactExact time
Most AI business applications are not medical devices and are not subject to pre-market validation requirements of comparable rigor; even when high-risk scenarios such as finance and hiring are involved, compliance review often lags behind product deployment.
1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
10/30/2026
First Seen
Valid until: 1/28/2027
Sources
Related Entities
Related Claims
UnverifiedMost consumer-grade AI systems lack clinical validation, and their recommendations are based more on correlation than on causation.78% similarUnverifiedIt is necessary to distinguish "technically feasible" from "commercially feasible": many AI capabilities hold up in the lab, but deployment costs, the cost of errors, and maintenance overhead may make the business model unviable.77% similarUnverifiedWhen enterprises procure AI, they focus more on the lower bound of risk (such as data security and compliance) than on the upper bound of capability.77% similarUnverifiedAll existing AI safety evaluation mechanisms have limitations including limited coverage, inconsistent evaluation standards, and companies having significant control over the scope of testing.77% similarVerifiedThe vast majority of AI risk disclosures lack substantiveness and are more boilerplate or compliance-oriented in nature.76% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1117168API
curl https://kongchang.com/api/v1/knowledge/claims/1117168MCP
get_claim(id=1117168)